Even higher use seen in patients without type 2 diabetes
THURSDAY, Oct. 9, 2025 (HealthDay News) — The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) before surgery rose 16-fold among patients undergoing metabolic and bariatric surgery from 2020 to 2024, according to a study presented at the annual meeting of the American College of Surgeons, held from Oct. 4 to 7 in Chicago.
Stefanie C. Rohde, M.D., from The Ohio State University Wexner Medical Center in Columbus, and colleagues examined population-level use of GLP-1 RAs before metabolic and bariatric surgery (MBS). The analysis included 373,308 unique patients who underwent primary MBS between 2020 and 2024.
The researchers found that from quarter 1 2020 to quarter 4 2024, the proportion of patients with at least one preoperative GLP-1 RA prescription increased from 5.6 to 26.9 percent. Among patients without type 2 diabetes, preoperative GLP-1 RA prescriptions rose 12-fold (from 1.6 to 19.5 percent) compared with threefold among patients with type 2 diabetes (from 14.7 to 44.5 percent). Increases in semaglutide and tirzepatide prescriptions primarily drove these trends.
“While patients previously believed they had to choose between GLP-1 receptor agonists and surgery, we”re now seeing that people are using both,” Rohde said in a statement.
Bariatric Surgery Is Effective Rescue Strategy After GLP-1 Receptor Agonist Failure 
Weight-Loss Surgery Produces Lasting Diabetes Remission 
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy 
Personalized Support Boosts Families" Genetic Testing for Hereditary Cancers 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
